<!DOCTYPE html>
<html>
<head>
<meta http-equiv="X-UA-Compatible" content="IE=Edge" />
<meta charset="utf-8" />
</head>

<body style="margin: 0;">

<div id="p187" style="overflow: hidden; position: relative; background-color: white; width: 1210px; height: 935px;">
<style class="shared-css" type="text/css" >
.t {
	transform-origin: bottom left;
	z-index: 2;
	position: absolute;
	white-space: pre;
	overflow: visible;
	line-height: 1.5;
}
.text-container {
	white-space: pre;
}
@supports (-webkit-touch-callout: none) {
	.text-container {
		white-space: normal;
	}
}
</style>
<style type="text/css" >

#t1_187{left:35px;bottom:24px;letter-spacing:-0.34px;word-spacing:0.13px;}
#t2_187{left:306px;bottom:30px;}
#t3_187{left:313px;bottom:24px;letter-spacing:0.16px;}
#t4_187{left:346px;bottom:30px;}
#t5_187{left:351px;bottom:24px;letter-spacing:-0.16px;word-spacing:-0.22px;}
#t6_187{left:517px;bottom:30px;}
#t7_187{left:524px;bottom:24px;letter-spacing:-0.28px;word-spacing:-0.09px;}
#t8_187{left:288px;bottom:860px;letter-spacing:0.11px;word-spacing:-0.55px;}
#t9_187{left:288px;bottom:829px;letter-spacing:0.27px;word-spacing:-0.69px;}
#ta_187{left:1115px;bottom:27px;letter-spacing:0.23px;}
#tb_187{left:35px;bottom:777px;letter-spacing:0.07px;word-spacing:-0.11px;}
#tc_187{left:35px;bottom:754px;letter-spacing:0.13px;word-spacing:-1.06px;}
#td_187{left:35px;bottom:731px;letter-spacing:0.09px;word-spacing:0.1px;}
#te_187{left:506px;bottom:731px;letter-spacing:0.02px;}
#tf_187{left:35px;bottom:707px;letter-spacing:0.18px;word-spacing:0.01px;}
#tg_187{left:386px;bottom:707px;letter-spacing:-0.11px;}
#th_187{left:405px;bottom:707px;letter-spacing:0.22px;}
#ti_187{left:35px;bottom:684px;letter-spacing:0.17px;}
#tj_187{left:183px;bottom:684px;letter-spacing:0.09px;word-spacing:-0.35px;}
#tk_187{left:35px;bottom:645px;letter-spacing:0.04px;word-spacing:-1.08px;}
#tl_187{left:35px;bottom:622px;letter-spacing:0.13px;word-spacing:0.06px;}
#tm_187{left:35px;bottom:599px;letter-spacing:0.19px;}
#tn_187{left:35px;bottom:575px;letter-spacing:0.05px;word-spacing:0.13px;}
#to_187{left:479px;bottom:583px;letter-spacing:-0.01px;}
#tp_187{left:502px;bottom:575px;letter-spacing:0.39px;word-spacing:-0.21px;}
#tq_187{left:35px;bottom:552px;letter-spacing:0.06px;word-spacing:-0.97px;}
#tr_187{left:35px;bottom:529px;letter-spacing:0.07px;word-spacing:0.12px;}
#ts_187{left:469px;bottom:536px;letter-spacing:-0.01px;}
#tt_187{left:488px;bottom:529px;letter-spacing:-0.01px;word-spacing:0.19px;}
#tu_187{left:35px;bottom:506px;letter-spacing:0.02px;word-spacing:0.16px;}
#tv_187{left:35px;bottom:482px;letter-spacing:0.26px;}
#tw_187{left:108px;bottom:490px;letter-spacing:0.12px;}
#tx_187{left:175px;bottom:482px;letter-spacing:0.27px;}
#ty_187{left:214px;bottom:482px;letter-spacing:0.21px;word-spacing:-0.02px;}
#tz_187{left:435px;bottom:482px;letter-spacing:-0.29px;}
#t10_187{left:468px;bottom:482px;letter-spacing:0.23px;word-spacing:-0.05px;}
#t11_187{left:35px;bottom:459px;letter-spacing:0.2px;word-spacing:-1.24px;}
#t12_187{left:187px;bottom:459px;letter-spacing:0.06px;word-spacing:-0.64px;}
#t13_187{left:35px;bottom:419px;letter-spacing:0.1px;word-spacing:0.09px;}
#t14_187{left:35px;bottom:396px;letter-spacing:0.04px;word-spacing:0.14px;}
#t15_187{left:35px;bottom:372px;letter-spacing:0.11px;word-spacing:0.07px;}
#t16_187{left:35px;bottom:349px;letter-spacing:0.1px;word-spacing:0.09px;}
#t17_187{left:330px;bottom:357px;letter-spacing:-0.01px;}
#t18_187{left:353px;bottom:349px;letter-spacing:0.27px;}
#t19_187{left:392px;bottom:349px;letter-spacing:0.19px;word-spacing:-0.01px;}
#t1a_187{left:35px;bottom:326px;letter-spacing:0.25px;}
#t1b_187{left:97px;bottom:326px;letter-spacing:0.13px;word-spacing:-1.17px;}
#t1c_187{left:357px;bottom:326px;letter-spacing:-0.31px;}
#t1d_187{left:389px;bottom:326px;letter-spacing:0.09px;word-spacing:-1.14px;}
#t1e_187{left:549px;bottom:326px;letter-spacing:0.17px;word-spacing:-1.22px;}
#t1f_187{left:35px;bottom:303px;letter-spacing:0.1px;word-spacing:-0.89px;}
#t1g_187{left:35px;bottom:280px;letter-spacing:0.1px;word-spacing:0.09px;}
#t1h_187{left:35px;bottom:256px;letter-spacing:0.12px;word-spacing:0.07px;}
#t1i_187{left:35px;bottom:233px;letter-spacing:0.02px;word-spacing:0.17px;}
#t1j_187{left:35px;bottom:210px;letter-spacing:0.27px;}
#t1k_187{left:112px;bottom:217px;letter-spacing:0.1px;}
#t1l_187{left:35px;bottom:173px;letter-spacing:-0.11px;word-spacing:0.53px;}
#t1m_187{left:35px;bottom:148px;letter-spacing:0.13px;word-spacing:0.05px;}
#t1n_187{left:455px;bottom:148px;letter-spacing:0.23px;word-spacing:-0.05px;}
#t1o_187{left:35px;bottom:124px;letter-spacing:0.18px;}
#t1p_187{left:398px;bottom:124px;letter-spacing:-0.29px;}
#t1q_187{left:431px;bottom:124px;letter-spacing:0.23px;word-spacing:-0.05px;}
#t1r_187{left:35px;bottom:101px;letter-spacing:0.19px;}
#t1s_187{left:441px;bottom:101px;letter-spacing:0.1px;word-spacing:0.09px;}
#t1t_187{left:35px;bottom:78px;letter-spacing:0.12px;word-spacing:-0.72px;}
#t1u_187{left:35px;bottom:55px;letter-spacing:0.17px;word-spacing:0.02px;}
#t1v_187{left:618px;bottom:777px;letter-spacing:0.21px;word-spacing:-0.02px;}
#t1w_187{left:618px;bottom:754px;letter-spacing:0.14px;word-spacing:0.05px;}
#t1x_187{left:618px;bottom:731px;letter-spacing:0.06px;word-spacing:0.12px;}
#t1y_187{left:618px;bottom:707px;letter-spacing:0.09px;word-spacing:-0.27px;}
#t1z_187{left:618px;bottom:684px;letter-spacing:0.16px;}
#t20_187{left:720px;bottom:684px;}
#t21_187{left:736px;bottom:684px;letter-spacing:0.15px;word-spacing:0.04px;}
#t22_187{left:618px;bottom:661px;letter-spacing:-0.02px;}
#t23_187{left:669px;bottom:668px;letter-spacing:-0.01px;}
#t24_187{left:691px;bottom:661px;letter-spacing:0.03px;word-spacing:-0.81px;}
#t25_187{left:618px;bottom:638px;letter-spacing:0.11px;word-spacing:-0.48px;}
#t26_187{left:618px;bottom:614px;letter-spacing:0.1px;word-spacing:0.08px;}
#t27_187{left:713px;bottom:622px;letter-spacing:-0.01px;}
#t28_187{left:618px;bottom:575px;letter-spacing:0.31px;}
#t29_187{left:618px;bottom:546px;letter-spacing:0.11px;word-spacing:0.08px;}
#t2a_187{left:618px;bottom:523px;letter-spacing:0.09px;word-spacing:-1.13px;}
#t2b_187{left:843px;bottom:523px;letter-spacing:0.13px;word-spacing:-0.29px;}
#t2c_187{left:618px;bottom:500px;letter-spacing:0.15px;word-spacing:0.04px;}
#t2d_187{left:618px;bottom:476px;letter-spacing:0.04px;word-spacing:0.14px;}
#t2e_187{left:618px;bottom:453px;letter-spacing:0.08px;word-spacing:-0.76px;}
#t2f_187{left:618px;bottom:430px;letter-spacing:0.09px;word-spacing:0.1px;}
#t2g_187{left:618px;bottom:387px;letter-spacing:-0.17px;word-spacing:2.04px;}
#t2h_187{left:618px;bottom:359px;letter-spacing:0.08px;word-spacing:0.11px;}
#t2i_187{left:618px;bottom:336px;letter-spacing:0.11px;word-spacing:0.18px;}
#t2j_187{left:618px;bottom:313px;letter-spacing:0.03px;word-spacing:-0.67px;}
#t2k_187{left:618px;bottom:289px;letter-spacing:-0.12px;}
#t2l_187{left:666px;bottom:297px;letter-spacing:-0.01px;}
#t2m_187{left:689px;bottom:289px;letter-spacing:0.04px;word-spacing:0.15px;}
#t2n_187{left:618px;bottom:266px;letter-spacing:0.21px;word-spacing:-0.02px;}
#t2o_187{left:799px;bottom:266px;letter-spacing:-0.31px;}
#t2p_187{left:832px;bottom:266px;letter-spacing:0.2px;word-spacing:-0.01px;}
#t2q_187{left:1018px;bottom:266px;letter-spacing:0.1px;word-spacing:0.1px;}
#t2r_187{left:618px;bottom:243px;letter-spacing:0.13px;word-spacing:0.06px;}
#t2s_187{left:618px;bottom:204px;letter-spacing:0.11px;word-spacing:0.07px;}
#t2t_187{left:618px;bottom:181px;letter-spacing:0.1px;word-spacing:-0.44px;}
#t2u_187{left:618px;bottom:157px;letter-spacing:0.05px;word-spacing:0.14px;}
#t2v_187{left:618px;bottom:134px;letter-spacing:0.08px;word-spacing:0.11px;}
#t2w_187{left:618px;bottom:111px;letter-spacing:0.01px;word-spacing:0.17px;}
#t2x_187{left:618px;bottom:88px;word-spacing:0.18px;}
#t2y_187{left:618px;bottom:64px;letter-spacing:-0.09px;word-spacing:0.28px;}
#t2z_187{left:768px;bottom:72px;}
#t30_187{left:812px;bottom:64px;letter-spacing:0.05px;word-spacing:-1.09px;}
#t31_187{left:23px;bottom:915px;letter-spacing:-0.14px;}

.s0_187{font-size:10px;font-family:ArialMT_5tg;color:#000;}
.s1_187{font-size:6px;font-family:ArialMT_5tg;color:#000;}
.s2_187{font-size:28px;font-family:Arial-BoldMT_5te;color:#000;}
.s3_187{font-size:17px;font-family:Arial-BoldMT_5te;color:#000;}
.s4_187{font-size:17px;font-family:ArialMT_5tg;color:#000;}
.s5_187{font-size:17px;font-family:Arial-ItalicMT_kb;color:#000;}
.s6_187{font-size:11px;font-family:ArialMT_5tg;color:#000;}
.s7_187{font-size:16px;font-family:Arial-BoldItalicMT_kg;color:#000;}
.s8_187{font-size:20px;font-family:Arial-BoldMT_5te;color:#000;}
.s9_187{font-size:11px;font-family:Helvetica, Arial, sans-serif;color:#000;}
</style>
<style id="fonts187" type="text/css" >

@font-face {
	font-family: Arial-BoldItalicMT_kg;
	src: url("fonts/Arial-BoldItalicMT_kg.woff") format("woff");
}

@font-face {
	font-family: Arial-BoldMT_5te;
	src: url("fonts/Arial-BoldMT_5te.woff") format("woff");
}

@font-face {
	font-family: Arial-ItalicMT_kb;
	src: url("fonts/Arial-ItalicMT_kb.woff") format("woff");
}

@font-face {
	font-family: ArialMT_5tg;
	src: url("fonts/ArialMT_5tg.woff") format("woff");
}

</style>
<div id="pg187Overlay" style="width:100%; height:100%; position:absolute; z-index:1; background-color:rgba(0,0,0,0); -webkit-user-select: none;"></div>
<div id="pg187" style="-webkit-user-select: none;"><object width="1210" height="935" data="187/187.svg" type="image/svg+xml" id="pdf187" style="width:1210px; height:935px; z-index: 0;"></object></div>
<div class="text-container"><span id="t1_187" class="t s0_187">Version 4.2024 © 2024 National Comprehensive Cancer Network </span>
<span id="t2_187" class="t s1_187">© </span>
<span id="t3_187" class="t s0_187">(NCCN </span>
<span id="t4_187" class="t s1_187">© </span>
<span id="t5_187" class="t s0_187">), All rights reserved. NCCN Guidelines </span>
<span id="t6_187" class="t s1_187">® </span>
<span id="t7_187" class="t s0_187">and this illustration may not be reproduced in any form without the express written permission of NCCN. </span>
<span id="t8_187" class="t s2_187">NCCN Guidelines Version 4.2024 </span>
<span id="t9_187" class="t s2_187">Head and Neck Cancers </span>
<span id="ta_187" class="t s3_187">MS-46 </span>
<span id="tb_187" class="t s4_187">NCCN Guidelines for Head and Neck Cancers). Surgery is also an option </span>
<span id="tc_187" class="t s4_187">for this patient population. For those patients whose disease persists after </span>
<span id="td_187" class="t s4_187">systemic therapy/RT or RT, surgical therapy is indicated (see </span><span id="te_187" class="t s5_187">Post </span>
<span id="tf_187" class="t s5_187">Systemic Therapy/RT or RT Neck Evaluation </span><span id="tg_187" class="t s4_187">in </span><span id="th_187" class="t s5_187">Follow-up </span>
<span id="ti_187" class="t s5_187">Recommendations </span><span id="tj_187" class="t s4_187">in the NCCN Guidelines for Head and Neck Cancers). </span>
<span id="tk_187" class="t s4_187">Induction chemotherapy with management based on response is an option </span>
<span id="tl_187" class="t s4_187">for all but T1–2, N0 glottic and supraglottic cancers. Based on the long- </span>
<span id="tm_187" class="t s4_187">term update of RTOG 91-11, induction chemotherapy is an option for </span>
<span id="tn_187" class="t s4_187">patients who require (are amenable to) total laryngectomy. </span>
<span id="to_187" class="t s6_187">288 </span>
<span id="tp_187" class="t s4_187">After a </span>
<span id="tq_187" class="t s4_187">complete or partial response with induction chemotherapy for patients with </span>
<span id="tr_187" class="t s4_187">laryngeal cancer, RT alone is recommended (category 1) </span>
<span id="ts_187" class="t s6_187">288 </span>
<span id="tt_187" class="t s4_187">; systemic </span>
<span id="tu_187" class="t s4_187">therapy/RT is a category 2B recommendation after a partial </span>
<span id="tv_187" class="t s4_187">response </span>
<span id="tw_187" class="t s6_187">302,303,579 </span>
<span id="tx_187" class="t s4_187">(see </span><span id="ty_187" class="t s5_187">Cancer of the Glottic Larynx </span><span id="tz_187" class="t s4_187">and </span><span id="t10_187" class="t s5_187">Cancer of the </span>
<span id="t11_187" class="t s5_187">Supraglottic Larynx </span><span id="t12_187" class="t s4_187">in the NCCN Guidelines for Head and Neck Cancers). </span>
<span id="t13_187" class="t s4_187">For patients with glottic and supraglottic T4a tumors, the recommended </span>
<span id="t14_187" class="t s4_187">treatment approach is total laryngectomy with possible hemi- or total </span>
<span id="t15_187" class="t s4_187">thyroidectomy and appropriate neck dissection(s) followed by adjuvant </span>
<span id="t16_187" class="t s4_187">treatment (RT or systemic therapy/RT) </span>
<span id="t17_187" class="t s6_187">580 </span>
<span id="t18_187" class="t s4_187">(see </span><span id="t19_187" class="t s5_187">Cancer of the Glottic </span>
<span id="t1a_187" class="t s5_187">Larynx, </span><span id="t1b_187" class="t s5_187">Cancer of the Supraglottic Larynx, </span><span id="t1c_187" class="t s4_187">and </span><span id="t1d_187" class="t s5_187">Principles of Surgery </span><span id="t1e_187" class="t s4_187">in the </span>
<span id="t1f_187" class="t s4_187">NCCN Guidelines for Head and Neck Cancers). For selected patients with </span>
<span id="t1g_187" class="t s4_187">T4a tumors who decline surgery, the NCCN Panel recommends: 1) </span>
<span id="t1h_187" class="t s4_187">considering concurrent systemic therapy/RT; 2) clinical trials; or 3) </span>
<span id="t1i_187" class="t s4_187">induction chemotherapy with additional management based on </span>
<span id="t1j_187" class="t s4_187">response. </span>
<span id="t1k_187" class="t s6_187">288,294 </span>
<span id="t1l_187" class="t s7_187">Radiation Therapy Fractionation </span>
<span id="t1m_187" class="t s4_187">Fractionation for RT is discussed in the algorithm (see </span><span id="t1n_187" class="t s5_187">Cancer of the </span>
<span id="t1o_187" class="t s5_187">Glottic Larynx: Principles of Radiation Therapy </span><span id="t1p_187" class="t s4_187">and </span><span id="t1q_187" class="t s5_187">Cancer of the </span>
<span id="t1r_187" class="t s5_187">Supraglottic Larynx: Principles of Radiation Therapy </span><span id="t1s_187" class="t s4_187">in the NCCN </span>
<span id="t1t_187" class="t s4_187">Guidelines for Head and Neck Cancers). For patients with T1, N0 disease </span>
<span id="t1u_187" class="t s4_187">of the glottic larynx, an accelerated dosing schedule of 63 Gy (2.25 </span>
<span id="t1v_187" class="t s4_187">Gy/fraction) is preferred over conventional fractionation (66 Gy, 2.0 </span>
<span id="t1w_187" class="t s4_187">Gy/fraction), based on results of a prospective randomized trial showing </span>
<span id="t1x_187" class="t s4_187">that this accelerated dosing schedule was associated with better 5-year </span>
<span id="t1y_187" class="t s4_187">local control, compared to a conventional dosing schedule (92% vs. 77%, </span>
<span id="t1z_187" class="t s4_187">respectively; </span><span id="t20_187" class="t s5_187">P </span><span id="t21_187" class="t s4_187">= .004), in 180 patients with stage I cancer of the glottic </span>
<span id="t22_187" class="t s4_187">larynx. </span>
<span id="t23_187" class="t s6_187">164 </span>
<span id="t24_187" class="t s4_187">A dosing schedule of 50–52 Gy (3.12–3.28 Gy/fraction) may also </span>
<span id="t25_187" class="t s4_187">be considered for patients with comorbidities or travel logistics or who are </span>
<span id="t26_187" class="t s4_187">older adults. </span>
<span id="t27_187" class="t s6_187">581 </span>
<span id="t28_187" class="t s3_187">Follow-up/Surveillance </span>
<span id="t29_187" class="t s4_187">Recommendations for surveillance are provided in the algorithm (see </span>
<span id="t2a_187" class="t s5_187">Follow-up Recommendations </span><span id="t2b_187" class="t s4_187">in the NCCN Guidelines for Head and Neck </span>
<span id="t2c_187" class="t s4_187">Cancers). Serial endoscopy is recommended during follow-up </span>
<span id="t2d_187" class="t s4_187">examinations and may be supplemented with high-resolution, advanced </span>
<span id="t2e_187" class="t s4_187">radiologic imaging because of the scarring, edema, and fibrosis that occur </span>
<span id="t2f_187" class="t s4_187">in the laryngeal tissues and neck after RT-based treatment. </span>
<span id="t2g_187" class="t s8_187">Paranasal Tumors (Maxillary and Ethmoid Sinus Tumors) </span>
<span id="t2h_187" class="t s4_187">Tumors of the paranasal sinuses are rare, and patients are often </span>
<span id="t2i_187" class="t s4_187">asymptomatic until late in the course of their disease. Tumors of the </span>
<span id="t2j_187" class="t s4_187">maxillary sinus are more common than those of the ethmoid sinus or nasal </span>
<span id="t2k_187" class="t s4_187">cavity. </span>
<span id="t2l_187" class="t s6_187">390 </span>
<span id="t2m_187" class="t s4_187">Workup is similar for ethmoid and maxillary sinus tumors (see </span>
<span id="t2n_187" class="t s5_187">Ethmoid Sinus Tumors </span><span id="t2o_187" class="t s4_187">and </span><span id="t2p_187" class="t s5_187">Maxillary Sinus Tumors </span><span id="t2q_187" class="t s4_187">in the NCCN </span>
<span id="t2r_187" class="t s4_187">Guidelines for Head and Neck Cancers). </span>
<span id="t2s_187" class="t s4_187">Although the most common histology for these tumors is squamous cell </span>
<span id="t2t_187" class="t s4_187">carcinoma, a variety of histologies have been reported including intestinal </span>
<span id="t2u_187" class="t s4_187">type adenocarcinoma, esthesioneuroblastoma (also known as olfactory </span>
<span id="t2v_187" class="t s4_187">neuroblastoma), minor salivary gland tumors, and undifferentiated </span>
<span id="t2w_187" class="t s4_187">carcinoma (eg, sinonasal undifferentiated carcinoma [SNUC], small cell </span>
<span id="t2x_187" class="t s4_187">carcinoma, midline NUT carcinoma, and sinonasal neuroendocrine </span>
<span id="t2y_187" class="t s4_187">carcinoma [SNEC]). </span>
<span id="t2z_187" class="t s6_187">582-586 </span>
<span id="t30_187" class="t s4_187">The defining features of esthesioneuroblastoma, </span>
<span id="t31_187" class="t s9_187">Printed by Fredd Merc on 8/29/2024 4:45:54 AM. For personal use only. Not approved for distribution. Copyright © 2024 National Comprehensive Cancer Network, Inc., All Rights Reserved. </span></div>

</div>
</body>
</html>
